Document Detail


Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
MedLine Citation:
PMID:  22726545     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ubiquitin-proteasome pathway (UPP) is a major protein degradation system that maintains homeostasis of intracellular proteins, involved in DNA repair, cell cycle regulation, cell proliferation, and drug resistance. Since numerous proteins are processed by proteasomes, their inhibition triggers dramatic disruption of protein homeostasis. Consequently, accumulation of polyubiquitinated proteins triggers different types of cellular stress responses, followed by growth arrest and cytotoxicity. Importantly, multiple myeloma (MM) cells are considered to have lower threshold against these stresses than other cell types, which makes these cells sensitive to proteasome inhibitors.
Authors:
Teru Hideshima; Kenneth C Anderson
Related Documents :
22905165 - The integrity of the cytokinesis machinery under stress conditions requires the glucan ...
12579295 - Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcino...
22416215 - The characteristics of supramammillary cells projecting to the hippocampus in stress re...
8583575 - Oxalate toxicity in llc-pk1 cells, a line of renal epithelial cells.
22905165 - The integrity of the cytokinesis machinery under stress conditions requires the glucan ...
2776005 - Phosphorus-31 nuclear magnetic resonance study of the c6 glioma cell line cultured on m...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in hematology     Volume:  49     ISSN:  1532-8686     ISO Abbreviation:  Semin. Hematol.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-25     Completed Date:  2013-06-10     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  0404514     Medline TA:  Semin Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  223-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA. teru_hideshima@dfci.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacology*
Cell Proliferation / drug effects
Homeostasis / drug effects
Humans
Multiple Myeloma / drug therapy,  metabolism,  pathology*
Proteasome Endopeptidase Complex / metabolism*
Proteasome Inhibitors / pharmacology*
Ubiquitin / antagonists & inhibitors,  metabolism
Grant Support
ID/Acronym/Agency:
P01 CA078378/CA/NCI NIH HHS; P50 CA100707/CA/NCI NIH HHS; R01 CA050947/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Proteasome Inhibitors; 0/Ubiquitin; EC 3.4.25.1/Proteasome Endopeptidase Complex
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The proteasome in terminal plasma cell differentiation.
Next Document:  Bortezomib combination therapy in multiple myeloma.